UCB SA (UCB.BR)
BE0003739530 - Common Stock
Taking everything into account, UCB scores 4 out of 10 in our fundamental rating. UCB was compared to 49 industry peers in the Pharmaceuticals industry. UCB has an average financial health and profitability rating. While showing a medium growth rate, UCB is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year UCB was profitable.
In the past year UCB had a positive cash flow from operations.
Each year in the past 5 years UCB has been profitable.
UCB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
UCB's Return On Assets of 2.21% is in line compared to the rest of the industry. UCB outperforms 51.11% of its industry peers.
UCB has a Return On Equity (3.82%) which is in line with its industry peers.
The Return On Invested Capital of UCB (3.17%) is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for UCB is below the industry average of 10.51%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.21% | ||
| ROE | 3.82% | ||
| ROIC | 3.17% |
ROA(3y)4.1%
ROA(5y)4.99%
ROE(3y)7.02%
ROE(5y)8.47%
ROIC(3y)5.56%
ROIC(5y)7.04%
1.3 Margins
UCB's Profit Margin of 6.53% is in line compared to the rest of the industry. UCB outperforms 55.56% of its industry peers.
In the last couple of years the Profit Margin of UCB has declined.
Looking at the Operating Margin, with a value of 9.75%, UCB is in line with its industry, outperforming 46.67% of the companies in the same industry.
UCB's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 67.50%, UCB perfoms like the industry average, outperforming 51.11% of the companies in the same industry.
UCB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.75% | ||
| PM (TTM) | 6.53% | ||
| GM | 67.5% |
OM growth 3Y-21.84%
OM growth 5Y-16.44%
PM growth 3Y-21.86%
PM growth 5Y-17.68%
GM growth 3Y-3.24%
GM growth 5Y-1.86%
2. Health
2.1 Basic Checks
UCB has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
UCB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, UCB has more shares outstanding
The debt/assets ratio for UCB is higher compared to a year ago.
2.2 Solvency
UCB has an Altman-Z score of 3.23. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of UCB (3.23) is better than 64.44% of its industry peers.
The Debt to FCF ratio of UCB is 6.83, which is on the high side as it means it would take UCB, 6.83 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 6.83, UCB perfoms like the industry average, outperforming 51.11% of the companies in the same industry.
A Debt/Equity ratio of 0.33 indicates that UCB is not too dependend on debt financing.
The Debt to Equity ratio of UCB (0.33) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 6.83 | ||
| Altman-Z | 3.23 |
ROIC/WACC0.44
WACC7.13%
2.3 Liquidity
UCB has a Current Ratio of 1.32. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.32, UCB perfoms like the industry average, outperforming 48.89% of the companies in the same industry.
A Quick Ratio of 0.92 indicates that UCB may have some problems paying its short term obligations.
The Quick ratio of UCB (0.92) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.32 | ||
| Quick Ratio | 0.92 |
3. Growth
3.1 Past
The earnings per share for UCB have decreased by -3.89% in the last year.
UCB shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -2.58% yearly.
Looking at the last year, UCB shows a decrease in Revenue. The Revenue has decreased by -4.80% in the last year.
UCB shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.54% yearly.
EPS 1Y (TTM)-3.89%
EPS 3Y-7.81%
EPS 5Y-2.58%
EPS growth Q2Q28.69%
Revenue 1Y (TTM)-4.8%
Revenue growth 3Y-0.6%
Revenue growth 5Y2.54%
Revenue growth Q2Q2.74%
3.2 Future
The Earnings Per Share is expected to grow by 18.74% on average over the next years. This is quite good.
UCB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.68% yearly.
EPS Next Y1.43%
EPS Next 2Y27.2%
EPS Next 3Y24.73%
EPS Next 5Y18.74%
Revenue Next Year8.36%
Revenue Next 2Y10.45%
Revenue Next 3Y9.99%
Revenue Next 5Y7.68%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 28.76, UCB can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as UCB.
UCB is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 25.25, which is the current average of the S&P500 Index.
UCB is valuated quite expensively with a Price/Forward Earnings ratio of 28.36.
Compared to the rest of the industry, the Price/Forward Earnings ratio of UCB is on the same level as its industry peers.
UCB is valuated rather expensively when we compare the Price/Forward Earnings ratio to 21.67, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.76 | ||
| Fwd PE | 28.36 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as UCB.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of UCB is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.52 | ||
| EV/EBITDA | 20.62 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates UCB does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as UCB's earnings are expected to grow with 24.73% in the coming years.
PEG (NY)20.07
PEG (5Y)N/A
EPS Next 2Y27.2%
EPS Next 3Y24.73%
5. Dividend
5.1 Amount
UCB has a yearly dividend return of 0.79%, which is pretty low.
UCB's Dividend Yield is comparable with the industry average which is at 2.61.
With a Dividend Yield of 0.79, UCB pays less dividend than the S&P500 average, which is at 2.45.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.45%.
Dividend Growth(5Y)2.45%
Div Incr Years5
Div Non Decr Years5
5.3 Sustainability
UCB pays out 73.47% of its income as dividend. This is not a sustainable payout ratio.
The dividend of UCB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP73.47%
EPS Next 2Y27.2%
EPS Next 3Y24.73%
UCB SA
EBR:UCB (4/24/2024, 7:00:00 PM)
120.8
-0.95 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap22.93B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.76 | ||
| Fwd PE | 28.36 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)20.07
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.21% | ||
| ROE | 3.82% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 9.75% | ||
| PM (TTM) | 6.53% | ||
| GM | 67.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.32 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-3.89%
EPS 3Y-7.81%
EPS 5Y
EPS growth Q2Q
EPS Next Y1.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.8%
Revenue growth 3Y-0.6%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y